Currently aimed at developing and manufacturing mammalian cell culture-based products, the expansion means Cook Pharmica also will offer formulation, filling and finishing services to customers. The facility will expand into aseptically filled parenteral vial and syringe products including, but not limited to, simple solutions and diluents, suspensions, vaccines, proteins and biologics.
Jerry Arthur, president of Cook Pharmica, said: “This expansion, which further diversifies our expansive portfolio of services, marks the dawn of a new era in our company’s growth, and is a testament to Cook’s commitment to contract biopharmaceutical manufacturing.”